Tiziana Life Sciences PLC Tiziana at J.P. Morgan Healthcare Conference 2021
January 11 2021 - 11:46AM
RNS Non-Regulatory
TIDMTILS
Tiziana Life Sciences PLC
11 January 2021
Tiziana Life Sciences plc
("Tiziana" or the "Company")
Tiziana Life Sciences to Present at J.P. Morgan Healthcare
Conference 2021
NEW YORK and LONDON - 11 January 2021 (GLOBE NEWSWIRE) - Tiziana
Life Sciences plc (NASDAQ: TLSA / AIM: TILS) ("Tiziana" or the
"Company"), a biotechnology company focused on innovative
therapeutics for oncology, inflammation, and infectious diseases,
today announced that it is participating in the J.P. Morgan 39th
Annual Healthcare Conference 2021.
Dr. Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences,
commented, "I look forward to sharing our exciting story with
conference attendees. With topline data from our COVID-19 trial
expected this month, multiple Phase 2 trial launches expected in
2021, and the potential application of Foralumab in a wide range of
autoimmune and inflammatory diseases in the longer-term, we are
well positioned to achieve a series of important milestones that
can provide a positive and lasting impact on our valuation in the
months and quarters ahead."
The J.P. Morgan Health Community Conference was created for
health leaders and transformers who are working to change the
current paradigms of health and wellness. The Community features
guests who are advancing, developing, designing, applying and
funding real solutions to improve personal and population
health.
Please visit http://www.tizianalifesciences.com/about-us/ or
www.TLSAinfo.com for more information and to view the latest
investor presentation.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules to
treat human disease in oncology and immunology. In addition to
Milciclib, the Company is also developing Foralumab for liver
diseases. Foralumab is the only fully human anti-CD3 monoclonal
antibody in clinical development in the world. This Phase 2
compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as nonalcoholic steatohepatitis
(NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes
(T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
U.S. Investor Contact:
RedChip Companies, Inc.
Dave Gentry
407-491-4498
dave@redchip.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAKFFFLDFEFA
(END) Dow Jones Newswires
January 11, 2021 11:46 ET (16:46 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Apr 2023 to Apr 2024